

Fabrizio Melani, Lucia Cecchi and Guido Filacchioni*

Dipartimento di Scienze Farmaceutiche, Università di Firenze,
50121 Firenze, Italy

Received October 5, 1983


Ethyl 3(5)-formylpyrazole-5(3)-carboxylate, 2-nitrobenzyl bromide or 2-nitrobenzoyl chloride are the starting basic materials to prepare with a few reaction steps, pyrazolo[5,1-*c*][1,4]benzodiazepines bearing at position 2 a substituted propionic chain (7-9) or bearing at position 5 a carbonyl group (12). Compounds 7-9, 12 are to be considered aza analogs of the antitumor antibiotic antramycin.

J. Heterocyclic Chem., **21**, 813 (1984).

Antramycin, tomaymycin and sibiromycin [1] are antitumor antibiotics containing as common feature the 5*H*-pyrrolo[2,1-*c*][1,4]benzodiazepine tricyclic ring system. Recently we reported [2] the synthesis of 5*H*-pyrazolo[5,1-*c*][1,4]benzodiazepine an isosteric analog of 5*H*-pyrrolo[2,1-*c*][1,4]benzodiazepine. In this paper we are reporting the synthesis of some pyrazolo[5,1-*c*][1,4]benzodiazepines bearing at position 2 a substituted propionic chain or bearing at position 5 a carbonyl group. These derivatives are related to the above cited antibiotics.

Allowing 2-nitrobenzyl bromide to react with ethyl 3(5)-formylpyrazole-5(3)-carboxylate (1) [3] the main product of the reaction was ethyl 1-(2-nitrobenzyl)-5-formylpyrazole-3-carboxylate (2) (Scheme 1). From the reaction

SCHEME 1




mixture a small amount of the isomer ethyl 1-(2-nitrobenzyl)-3-formylpyrazole-5-carboxylate (3) was even isolated. Catalytic reduction of 2 yielded ethyl 5*H*-10,11-dihydropyrazolo[5,1-*c*][1,4]benzodiazepine-2-carboxylate (4) which structure is supported by ir and pmr spectra. The pmr spectrum of 4 shows, among the others, a signal of an exchangeable proton and two signals at δ 4.45 and 5.52 which, in the literature data [2], could be attributed to the C₁₁ and C₅ protons respectively. The ir spectrum shows absorption bands of the NH and the CO ester at 3330 and 1735 cm⁻¹ respectively. Compound 4 was treated with lithium aluminium hydride to afford the 2-hydroxymethyl-5*H*-10,11-dihydropyrazolo[5,1-*c*][1,4]benzodiazepine (5). The latter was transformed into the corresponding 2-bromomethyl derivative 6 using phosphorus tribromide. When diethyl malonate was allowed to react with 6 it gave rise to the ethyl 3-(5*H*-10,11-dihydropyrazolo[5,1-*c*][1,4]benzodiazepin-2-yl)-2-carbethoxypropionate (7). Likewise were prepared compounds 8 and 9 reacting 6 with ethyl acetoacetate or ethyl cyanoacetate respectively.

This pathway is facile and convenient and allowed us to reach our aim with a few reaction steps. Moreover, compound 5 was first prepared reacting with lithium aluminium hydride, methyl 5,10-dihydro-11-oxopyrazolo[5,1-*c*][1,4]benzodiazepine-2-carboxylate (10) [2]. However the reduction of compound 10 proceeded with very poor yields and hence we do not suggest the use of this procedure.

The synthesis of the pyrazolobenzodiazepine bearing a carbonyl group at position 5 was achieved by reacting 2-nitrobenzoyl chloride with 1 (Scheme 2). From the reaction mixture only the isomer ethyl 1-(2-nitrobenzoyl)-5-formylpyrazole-3-carboxylate (11) was isolated. Compound 11 was catalytically reduced to give rise to the ethyl 10,11-dihydro-5-oxopyrazolo[5,1-*c*][1,4]benzodiazepine-2-carboxylate (12). The pmr spectrum of 12 shows, among the others, two protons at the C₁₁ (δ 4.42), one exchangeable proton and a C₆ proton at low fields (δ 8.3-8.5). The high δ value of the C₆ proton is due to the presence of the near carbonyl group. The characteristic absorption bands of the NH, CO ester and CO amide at 3350, 1730 and 1680 cm⁻¹ re-

spectively are present in the ir spectrum.

SCHEME 2



In an attempt to prepare methyl 10*H*-5,11-dioxopyrazolo[5,1-*c*][1,4]benzodiazepine-2-carboxylate we reacted 2-nitrobenzoyl chloride with dimethyl pyrazole-3,5-dicarboxylate. Catalytic reduction of the resulting nitro derivative **13** gave rise to the dimethyl 1-(2-aminobenzoyl)pyrazole-3,5-dicarboxylate (**14**). Unfortunately we were unable to cyclize the amino derivative **14** by heating it at room or at reduced pressure or by using cyclizing agents. In every case the cleavage of the aroyl group ensued, the starting dimethyl pyrazole-3,5-dicarboxylate being recovered.

All the compounds synthesized are characterized by elemental analysis, ir and pmr spectra. Furthermore the structure of compound **12** was confirmed by the mass spectrum.

EXPERIMENTAL

All melting points were determined on a Büchi 510 capillary melting point apparatus and are uncorrected. The ir spectra were taken in nujol mull with a Perkin-Elmer 337 spectrophotometer. The pmr spectra were recorded with a Varian EM 360 instrument: chemical shifts are reported in δ (ppm) downfield from internal TMS. Mass spectra were run on a Perkin-Elmer 270 mass spectrometer (70 eV ionizing voltage). Column chromatography was run on silica gel 60 (Merck), 70-230 mesh (gravity flow). Preparative thin layer chromatography was performed on precoated silica gel 60 Merck F₂₅₄ plates (layer thickness 2 mm).

Ethyl 1-(2-Nitrobenzyl)-5-formylpyrazole-3-carboxylate (**2**) and Ethyl 1-(2-Nitrobenzyl)-3-formylpyrazole-5-carboxylate (**3**).

A suspension of 3.0 g (17.8 mmoles) of **1** and 0.7 g (17.8 mmoles) of potassium in 150 ml of anhydrous tetrahydrofuran was refluxed for 3 hours. After cooling 3.9 g (17.8 mmoles) of 2-nitrobenzyl bromide was added and the mixture was refluxed for 5 hours. The reaction was carried out under a flow of nitrogen. The precipitate was filtered off and the solution was taken to dryness to give a mixture of compound **2** and **3**. Recrystallization from ethanol gave only compound **2** (3.7 g, 69%), white needles, mp 144-146°; ir: 3120 (w), 1730 (vs), 1680 (vs), 1535 (vs), 1350 (s), 1245 (vs), 1160 (m), 1105 (m), 1035 (m), 860 (m), 765 (s), 725 (s) cm⁻¹; pmr (deuteriochloroform): 1.42 (t, 3H, CH₃), 4.42 (q, 2H, CH₂), 6.22 (s, 2H, CH₂), 6.5-6.8 (m, 1H, benzene proton), 7.3-7.6 (m, 3H, 2 benzene protons and 1 pyrazole proton), 8.0-8.3 (m, 1H, benzene proton), 9.83 (s, 1H, formyl proton).

Anal. Calcd. for C₁₄H₁₃N₃O₅: C, 55.45; H, 4.32; N, 13.86. Found: C, 55.27; H, 4.46; N, 13.67.

The mother liquor containing compounds **2** and **3** was taken to dryness and the two isomers were separated by column chromatography (eluting system: benzene/ethyl acetate 9:1). The first running band afforded compound **3** (0.5 g, 10%) as white needles, mp 65-67° (from ethyl ether/light petroleum); ir: 3120 (s), 1730 (vs), 1700 (vs), 1530 (vs), 1350 (vs), 1280 (vs), 1205 (s), 1140 (s), 1105 (s), 1020 (m), 790 (m), 775 (m), 765 (m), 725 (vs) cm⁻¹; pmr (deuteriochloroform): 1.28 (t, 3H, CH₃), 4.28 (q, 2H, CH₂), 6.25 (s, 2H, CH₂), 6.6-6.8 (m, 1H, benzene proton), 7.3-7.6 (m, 3H, 2 benzene protons and 1 pyrazole proton), 8.0-8.3 (m, 1H, benzene proton), 10.00 (s, 1H, formyl proton).

Anal. Calcd. for C₁₄H₁₃N₃O₅: C, 55.45; H, 4.32; N, 13.86. Found: C, 55.48; H, 4.37; N, 14.22.

The second running band consisted in a second crop of compound **2** (0.6 g, overall yield 80%).

Ethyl 5*H*-10,11-Dihydropyrazolo[5,1-*c*][1,4]benzodiazepine-2-carboxylate (**4**).

To a solution of 1.5 g (5.0 mmoles) of **2** in 200 ml of ethyl acetate 0.7 g of 10% Pd/C was added. The mixture was hydrogenated in a Parr apparatus at 50 psi for 6 hours. Removal of the catalyst and evaporation of the solvent afforded a solid residue which was recrystallized from ethanol giving 0.85 g (67%) of compound **4**. White crystals, mp 169-171°; ir: 3330 (m), 1735 (vs), 1500 (m), 1230 (vs), 1190 (m), 1140 (m), 1105 (m), 1030 (m), 730 (m) cm⁻¹; pmr (deuteriochloroform): 1.37 (t, 3H, CH₃), 3.8-4.6 (m, 5H, CH₂ester, 11-CH₂ and NH, the latter exchanges with deuterium oxide), 5.52 (s, 2H, 5-CH₂), 6.5-7.3 (m, 5H, 4 benzene protons and 1 pyrazole proton).

Anal. Calcd. for C₁₄H₁₅N₃O₂: C, 65.36; H, 5.88; N, 16.33. Found: C, 65.49; H, 5.91; N, 16.54.

2-Hydroxymethyl-5*H*-10,11-dihydropyrazolo[5,1-*c*][1,4]benzodiazepine (**5**).

A) To a suspension of 0.6 g of lithium aluminium hydride in 200 ml of anhydrous tetrahydrofuran a solution of 1.3 g (5.0 mmoles) of **4** in 50 ml of anhydrous tetrahydrofuran was added dropwise. The mixture was refluxed for 12 hours and set aside overnight. Addition of crushed ice, filtration and evaporation of the solvent yielded crude **5** which was recrystallized from benzene giving 0.8 g (73%).

B) Methyl 5,10-dihydro-11-oxopyrazolo[5,1-*c*][1,4]benzodiazepine-2-carboxylate (**10**) (1.0 g, 3.9 mmoles) and lithium aluminium hydride (1.0 g) were allowed to react as above described to give 0.2 g (20%) of compound **5**, white crystals, mp 141-143° (from benzene); ir: 3340 (m), 3400-2300 (br), 1500 (m), 1620 (w), 1350 (m), 1320 (m), 1040 (s), 1000 (vs), 735 (vs) cm⁻¹; pmr (DMSO-*d*₆): 4.2-4.6 (m, 4H, CH₂OH and 11-CH₂, when treated with deuterium oxide it becomes a broad singlet at 4.42), 4.90 (t, 1H, OH, J_{CH,OH} = 5.5 Hz, it exchanges with deuterium oxide), 5.40 (s, 2H, 5-CH₂), 5.8-6.2 (br s, 2H, 1 pyrazole proton and NH, it becomes a singlet at 6.12 when treated with deuterium oxide), 6.3-7.2 (m, 4H, 4 benzene protons).

Anal. Calcd. for C₁₂H₁₃N₃O: C, 66.96; H, 6.09; N, 19.52. Found: C, 66.64; H, 6.03; N, 19.30.

5*H*-10,11-Dihydro-2-bromomethylpyrazolo[5,1-*c*][1,4]benzodiazepine (**6**).

A solution of 1.0 g (4.6 mmoles) of **5** in 5 ml of phosphorus tribromide was heated under stirring at 70° for 6 hours. After cooling crushed ice, ethyl acetate and 6 *N* sodium hydroxide (pH 9) were added. The organic layer was separated and dried (sodium sulfate). After evaporation of the solvent the residue was recrystallized from ethyl acetate giving 0.9 g (68%), white needles, mp > 300°; ir: 3280 (vs), 1610 (s), 1500 (s), 1340 (m), 1315 (m), 1265 (m), 1210 (s), 1145 (m), 1100 (m), 1020 (m), 805 (m), 750 (s), 575 (s) cm⁻¹.

Anal. Calcd. for C₁₂H₁₂BrN₃: C, 51.82; H, 4.35; N, 15.11. Found: C, 51.55; H, 4.24; N, 15.32.

Ethyl 3-(5*H*-10,11-Dihydropyrazolo[5,1-*c*][1,4]benzodiazepin-2-yl)-2-carboxypropionate (**7**).

A suspension of 0.28 g (1.8 mmoles) of diethyl malonate and 0.07 g (1.8 mmoles) of potassium in 60 ml of anhydrous benzene was refluxed for 4 hours. After cooling 0.5 g (1.8 mmoles) of compound **6** was added and the mixture was refluxed for 3 hours. The precipitate was filtered off and the solution was taken to dryness. The residue was purified through a column chromatography (eluting system: benzene/ethyl acetate 1:1) giving 0.4 g (62%), white crystals, mp 58-60° (from cyclohexane); ir: 3260 (s), 1730 (vs), 1610 (w), 1500 (w), 1300 (m), 1270 (s), 1240 (s), 1195 (m), 1150 (w), 1030 (m), 740 (m) cm⁻¹; pmr (deuteriochloroform): 1.21 (t, 6H, 2CH₃), 3.20 (d, 2H, CH₂CH, J_{CH₂CH} = 8 Hz), 3.6-4.5 (m, 8H, 2CH₂-CH₃, 11-CH₂, CH-CH₂ and NH, the latter exchanges with deuterium oxide), 5.38 (s, 2H, 5-CH₂), 5.90 (s, 1H, pyrazole proton), 6.5-7.3 (m, 4H, 4 benzene protons).

Anal. Calcd. for C₁₉H₂₃N₃O₄: C, 63.85; H, 6.49; N, 11.76. Found: C, 64.00; H, 6.21; N, 11.98.

Ethyl 3-(5*H*-10,11-Dihydropyrazolo[5,1-*c*][1,4]benzodiazepin-2-yl)-2-acetylpropionate (**8**).

Compound **6** (0.5 g, 1.8 mmoles), potassium (0.07 g, 1.8 mmoles) and ethyl acetoacetate (0.23 g, 1.8 mmoles) were reacted as described above to obtain compound **7**. The crude material was purified through a column chromatography (eluting system: chloroform/acetonitrile 9:1) giving 0.35 g (59%) of a white oil; ir: 3400 (s), 1740 (vs), 1720 (vs), 1610 (s), 1500 (s), 1320 (m), 1265 (s), 1150 (m), 1020 (m), 750 (s) cm⁻¹; pmr (deuteriochloroform): 1.21 (t, 3H, CH₃-CH₂), 2.24 (s, 3H, CH₃-CO), 3.13 (d, 2H, CH₂CH, J_{CH₂CH} = 8 Hz), 3.3-3.6 (br s, 1H, NH, it exchanges with deuterium oxide), 3.8-4.5 (m, 5H, CH-CH₂, CH₂-CH₃ and 11-CH₂), 5.32 (s, 2H, 5-CH₂), 5.88 (s, 1H, pyrazole proton), 6.5-7.3 (m, 4H, 4 benzene protons).

The picrate was obtained as yellow crystals, mp 136-138° (from ethyl ether).

Anal. Calcd. for C₂₄H₂₄N₄O₁₀: C, 51.80; H, 4.35; N, 15.10. Found: C, 51.67; H, 4.40; N, 15.12.

Ethyl 3-(5*H*-10,11-Dihydropyrazolo[5,1-*c*][1,4]benzodiazepin-2-yl)-2-cyanopropionate (**9**).

Compound **6** (0.5 g, 1.8 mmoles), potassium (0.07 g, 1.8 mmoles) and ethyl cyanoacetate (0.2 g, 1.8 mmoles) were reacted as above described to obtain compound **7**. The crude material was purified through a column chromatography (eluting system: chloroform/acetonitrile 9:1) giving 0.4 g (71%) of compound **9**, white needles, mp 94-96° (from cyclohexane); ir: 3310 (s), 2250 (w), 1730 (vs), 1620 (m), 1510 (s), 1400 (m), 1320 (m), 1280 (s), 1165 (w), 1070 (w), 1025 (m), 860 (w), 745 (s), 730 (w) cm⁻¹; pmr (deuteriochloroform): 1.28 (t, 3H, CH₃), 3.20 (m, 2H, AB part of an ABX system, CH₂-CH), 3.7-4.5 (m, 6H, CH₂-CH₃, 11-CH₂, CH-CH₂ and NH, the latter exchanges with deuterium oxide), 5.40 (s, 2H, 5-CH₂), 6.05 (s, 1H, pyrazole proton), 6.5-7.3 (m, 4H, 4 benzene protons).

Anal. Calcd. for C₁₇H₁₈N₄O₂: C, 65.78; H, 5.84; N, 18.05. Found: C, 65.66; H, 6.01; N, 18.30.

Ethyl 1-(2-Nitrobenzoyl)-5-formylpyrazole-3-carboxylate (**11**).

A suspension of 1.72 g (10.3 mmoles) of **1** and 0.4 g (10.3 mmoles) of potassium in 50 ml of anhydrous tetrahydrofuran was refluxed for 6 hours. After cooling 1.9 g (10.3 mmoles) of 2-nitrobenzoyl chloride was

added. The mixture was left aside overnight. The reaction was carried out under a flow of nitrogen. The precipitate was filtered off and the solution was taken to dryness to give a crude which was recrystallized from ethyl acetate giving 1.3 g (40%), white crystals, mp 146-147°; ir: 1760 (vs), 1740 (vs), 1690 (s), 1540 (vs), 1360 (vs), 1330 (vs), 1255 (vs), 1210 (vs), 1145 (m), 1030 (m), 930 (s), 860 (m), 785 (m), 735 (m), 710 (s) cm⁻¹; pmr (deuteriochloroform): 1.33 (t, 3H, CH₃), 4.33 (q, 2H, CH₂), 7.55 (s, 1H, pyrazole proton), 7.7-8.0 (m, 3H, 3 benzene protons), 8.1-8.5 (m, 1H, C₆ benzene proton), 10.70 (s, 1H, formyl proton).

Anal. Calcd. for C₁₄H₁₁N₃O₆: C, 53.00; H, 3.49; N, 13.24. Found: C, 53.17; H, 3.39; N, 13.27.

Ethyl 10,11-Dihydro-5-oxopyrazolo[5,1-*c*][1,4]benzodiazepine-2-carboxylate (**12**).

To a solution of 0.7 g (2.2 mmoles) of **11** in 100 ml of ethyl acetate 0.3 g of 10% Pd/C was added. The mixture was hydrogenated in a Parr apparatus at 50 psi for 8 hours. Removal of the catalyst and evaporation of the solvent afforded a crude material which was purified by preparative tlc (eluting system: chloroform/acetonitrile 8:2), second running band, giving 0.2 g (33%) of compound **12**, yellow crystals, mp 189-191°; ir: 3350 (s), 1730 (s), 1680 (vs), 1620 (m), 1530 (m), 1360 (m), 1310 (m), 1235 (s), 1165 (m), 1145 (m), 1105 (m), 1030 (m), 995 (m), 975 (m), 945 (m), 745 (s) cm⁻¹; pmr (deuteriochloroform): 1.36 (t, 3H, CH₃), 4.2-4.6 (m, 4H, CH₂-CH₃ and 11-CH₂), 5.4 (br s, 1H, NH, it exchanges with deuterium oxide), 6.7-7.6 (m, 4H, 3 benzene protons and 1 pyrazole proton), 8.3-8.5 (m, 1H, C₆ benzene proton).

Anal. Calcd. for C₁₄H₁₃N₃O₃: C, 61.99; H, 4.83; N, 15.49. Found: C, 61.84; H, 4.94; N, 15.15.

Dimethyl 1-(2-Nitrobenzoyl)pyrazole-3,5-dicarboxylate (**13**).

A suspension of 1.8 g (10.2 mmoles) of dimethyl pyrazole-3,5-dicarboxylate and 0.31 g (8.0 mmoles) of potassium in 100 ml of anhydrous tetrahydrofuran was refluxed for 3 hours. After cooling 1.5 g (8.0 mmoles) of 2-nitrobenzoyl chloride was added and the mixture was refluxed for 2 hours. The reaction was carried out under a nitrogen flow. The precipitate was filtered off and the solution was taken to dryness to give a residue which was recrystallized from ethanol giving 2.3 g (86%) of **13**, white crystals, mp 137-139°; ir: 1770 (vs), 1750 (vs), 1720 (vs), 1540 (vs), 1350 (vs), 1300 (vs), 1270 (vs), 1235 (vs), 1205 (vs), 1125 (m), 1090 (m), 995 (m), 910 (vs), 855 (m), 825 (m), 710 (vs) cm⁻¹; pmr (deuteriochloroform): 3.84 (s, 3H, CH₃), 4.00 (s, 3H, CH₃), 7.23 (s, 1H, pyrazole proton), 7.6-7.9 (m, 3H, 3 benzene protons), 8.1-8.4 (m, 1H, C₆ benzene proton).

Anal. Calcd. for C₁₄H₁₁N₃O₇: C, 50.46; H, 3.33; N, 12.61. Found: C, 50.10; H, 3.26; N, 12.56.

Dimethyl 1-(2-Aminobenzoyl)pyrazole-3,5-dicarboxylate (**14**).

To a solution of 2.0 g (6.0 mmoles) of **13** in 100 ml of ethyl acetate 0.5 g of 10% Pd/C was added. The mixture was hydrogenated in a Parr apparatus at 50 psi for 6 hours. Removal of the catalyst and evaporation of the solvent afforded a solid residue which was recrystallized from ethanol giving 1.4 g (77%) of compound **14**, yellow crystals, mp 162-165°; ir: 3470 (vs), 3370 (vs), 3140 (w), 1740 (vs), 1720 (vs), 1690 (vs), 1630 (vs), 1560 (s), 1300 (s), 1280 (s), 1235 (vs), 1205 (s), 1175 (m), 1110 (m), 1100 (m), 1015 (m), 915 (s), 760 (vs), 685 (m) cm⁻¹; pmr (deuteriochloroform): 3.86 (s, 3H, CH₃), 3.96 (s, 3H, CH₃), 6.15 (br s, 2H, NH₂ they exchange with deuterium oxide), 6.4-7.5 (m, 5H, 4 benzene protons and 1 pyrazole proton).

Anal. Calcd. for C₁₄H₁₃N₃O₅: C, 55.45; H, 4.32; N, 13.86. Found: C, 55.15; H, 4.45; N, 14.00.

REFERENCES AND NOTES

- [1] L. H. Hurley, *J. Antibiot.*, **30**, 349 (1977).
- [2] L. Cecchi and G. Filacchioni, *J. Heterocyclic Chem.*, **20**, 871 (1983) and references cited therein.
- [3] R. Hüttel, *Chem. Ber.*, **74**, 1680 (1941).